Lilly's $3.8 Billion Vaccine Bets: A Quiet Shift Now
Lilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
Explore strategies to prevent wasting your credit card benefits and maximize your rewards potential.
14,761 articlesLilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
Wegovy continues to lead the U.S. GLP-1 market despite Eli Lilly's Foundayo launch. Investors are weighing uptake, pa...
Starting with $500 can still build a solid foundation for long-term wealth. This guide reveals how to target the smar...
NUKZ is in focus as two pivotal drivers could redefine its trajectory: big-hyperscaler nuclear agreements and the rol...
Bark is shaping its path in a competitive pet market. This guide breaks down what to expect in bark (bark) 2026 earni...
Cloud giants are expanding, yet the super micro computer stock slid on a capital-raise plan. This article breaks down...
Devon Energy shares surged after an updated 2026 forecast highlighted stronger cash flow and a solid balance sheet. T...
Rising costs in AI model development are reshaping the investing landscape. This guide explains the drivers, the semi...
Crypto markets rebound as ripple’s (xrp) potential and Solana price outlook draw attention. Key on-chain data and ins...
A leading venture capital investor argues that Elon Musk has largely solved the physics hurdles for SpaceX’s Starlink...
Markets react as Trump signals an interim Iran deal to reopen the Strait of Hormuz. The move could ease shipping disr...
Tilray is expanding beyond its home market, but the stock market isn’t fully pricing in that growth. This article bre...